For instance, Filanesib, an inhibitor of KIF11, recently completed Phase 2 clinical trial for multiple myeloma treatment, with a response rate of 16% and progression free survival value of 1.6 months [46], now Filanesib has been scheduled to enter Phase 3 clinical trials for multiple myeloma [47]. Here, KIF11 is linked to plasma cell myeloma.